PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjgenpracRCGP homepageJ R Coll Gen Pract at PubMed CentralBJGP at RCGPBJGP at RCGP
 
Br J Gen Pract. 1995 May; 45(394): 261–268.
PMCID: PMC1239233

Idiopathic Parkinson's disease: epidemiology, diagnosis and management.

Abstract

Since the introduction of levodopa therapy for idiopathic Parkinson's disease over 20 years ago, there has been an awakening of research interest in this chronic neuro-degenerative disorder. This paper describes current understanding of the role of genetic and environmental factors in the aetiology of idiopathic Parkinson's disease and problems associated with both diagnosis and management. It briefly outlines both pharmacological and non-pharmacological options for treatment. Despite an increasing armoury of available treatments, the optimum management for this condition remains controversial.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Mutch WJ, Dingwall-Fordyce I, Downie AW, Paterson JG, Roy SK. Parkinson's disease in a Scottish city. Br Med J (Clin Res Ed) 1986 Feb 22;292(6519):534–536. [PMC free article] [PubMed]
  • Wade DT, Hewer RL. Epidemiology of some neurological diseases with special reference to work load on the NHS. Int Rehabil Med. 1987;8(3):129–137. [PubMed]
  • Duvoisin RC. Genetics of Parkinson's disease. Adv Neurol. 1987;45:307–312. [PubMed]
  • Johnson WG, Hodge SE, Duvoisin R. Twin studies and the genetics of Parkinson's disease--a reappraisal. Mov Disord. 1990;5(3):187–194. [PubMed]
  • Ward CD, Duvoisin RC, Ince SE, Nutt JD, Eldridge R, Calne DB. Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology. 1983 Jul;33(7):815–824. [PubMed]
  • Marsden CD. Parkinson's disease in twins. J Neurol Neurosurg Psychiatry. 1987 Jan;50(1):105–106. [PMC free article] [PubMed]
  • Marttila RJ, Kaprio J, Koskenvuo M, Rinne UK. Parkinson's disease in a nationwide twin cohort. Neurology. 1988 Aug;38(8):1217–1219. [PubMed]
  • Vieregge P, Schiffke KA, Friedrich HJ, Müller B, Ludin HP. Parkinson's disease in twins. Neurology. 1992 Aug;42(8):1453–1461. [PubMed]
  • Marttila RJ, Rinne UK. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson's disease. A case-control study. Clin Neurol Neurosurg. 1976;79(1):46–56. [PubMed]
  • Martin WE, Young WI, Anderson VE. Parkinson's disease. A genetic study. Brain. 1973 Sep;96(3):495–506. [PubMed]
  • Roy M, Boyer L, Barbeau A. A prospective study of 50 cases of familial Parkinson's disease. Can J Neurol Sci. 1983 Feb;10(1):37–42. [PubMed]
  • Burn DJ, Mark MH, Playford ED, Maraganore DM, Zimmerman TR, Jr, Duvoisin RC, Harding AE, Marsden CD, Brooks DJ. Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology. 1992 Oct;42(10):1894–1900. [PubMed]
  • Golbe LI, Di Iorio G, Bonavita V, Miller DC, Duvoisin RC. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol. 1990 Mar;27(3):276–282. [PubMed]
  • Ludin SM, Ludin HP. Is Parkinson's disease of early onset a separate disease entity? J Neurol. 1989 May;236(4):203–207. [PubMed]
  • Maraganore DM, Harding AE, Marsden CD. A clinical and genetic study of familial Parkinson's disease. Mov Disord. 1991;6(3):205–211. [PubMed]
  • Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet. 1992 Apr 25;339(8800):1017–1018. [PubMed]
  • Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, Sturman SG, Schapira AH, Williams AC, Maranganore DM, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet. 1992 Jun 6;339(8806):1375–1377. [PubMed]
  • Steventon GB, Heafield MT, Waring RH, Williams AC. Xenobiotic metabolism in Parkinson's disease. Neurology. 1989 Jul;39(7):883–887. [PubMed]
  • Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology. 1985 Jun;35(6):841–845. [PubMed]
  • Schoenberg BS, Osuntokun BO, Adeuja AO, Bademosi O, Nottidge V, Anderson DW, Haerer AF. Comparison of the prevalence of Parkinson's disease in black populations in the rural United States and in rural Nigeria: door-to-door community studies. Neurology. 1988 Apr;38(4):645–646. [PubMed]
  • POSKANZER DC, SCHWAB RS. COHORT ANALYSIS OF PARKINSON'S SYNDROME: EVIDENCE FOR A SINGLE ETIOLOGY RELATED TO SUBCLINICAL INFECTION ABOUT 1920. J Chronic Dis. 1963 Sep;16:961–973. [PubMed]
  • Ben-Shlomo Y, Finnan F, Allwright S, Davey Smith G. The epidemiology of Parkinson's disease in the Republic of Ireland: observations from routine data sources. Ir Med J. 1993 Nov-Dec;86(6):190–194. [PubMed]
  • Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol. 1984 Sep;16(3):278–282. [PubMed]
  • Calne DB, Langston JW. Aetiology of Parkinson's disease. Lancet. 1983 Dec 24;2(8365-66):1457–1459. [PubMed]
  • Elizan TS, Casals J. The viral hypothesis in parkinsonism. J Neural Transm Suppl. 1983;19:75–88. [PubMed]
  • Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983 Feb 25;219(4587):979–980. [PubMed]
  • Koller WC. Paraquat and Parkinson's disease. Neurology. 1986 Aug;36(8):1147–1147. [PubMed]
  • Sanchez-Ramos JR, Hefti F, Weiner WJ. Paraquat and Parkinson's disease. Neurology. 1987 Apr;37(4):728–728. [PubMed]
  • Barbeau A, Roy M, Bernier G, Campanella G, Paris S. Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. Can J Neurol Sci. 1987 Feb;14(1):36–41. [PubMed]
  • Ho SC, Woo J, Lee CM. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology. 1989 Oct;39(10):1314–1318. [PubMed]
  • Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology. 1992 Jul;42(7):1328–1335. [PubMed]
  • Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson's disease. Neurology. 1993 Jun;43(6):1150–1158. [PubMed]
  • Koller W, Vetere-Overfield B, Gray C, Alexander C, Chin T, Dolezal J, Hassanein R, Tanner C. Environmental risk factors in Parkinson's disease. Neurology. 1990 Aug;40(8):1218–1221. [PubMed]
  • Baumann RJ, Jameson HD, McKean HE, Haack DG, Weisberg LM. Cigarette smoking and Parkinson disease: 1. Comparison of cases with matched neighbors. Neurology. 1980 Aug;30(8):839–843. [PubMed]
  • Granieri E, Carreras M, Casetta I, Govoni V, Tola MR, Paolino E, Monetti VC, De Bastiani P. Parkinson's disease in Ferrara, Italy, 1967 through 1987. Arch Neurol. 1991 Aug;48(8):854–857. [PubMed]
  • Kessler II. Epidemiologic studies of Parkinson's disease. 3. A community-based survey. Am J Epidemiol. 1972 Oct;96(4):242–254. [PubMed]
  • Semchuk KM, Love EJ, Lee RG. Parkinson's disease and exposure to rural environmental factors: a population based case-control study. Can J Neurol Sci. 1991 Aug;18(3):279–286. [PubMed]
  • Stern M, Dulaney E, Gruber SB, Golbe L, Bergen M, Hurtig H, Gollomp S, Stolley P. The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. Arch Neurol. 1991 Sep;48(9):903–907. [PubMed]
  • Rajput AH, Uitti RJ, Stern W, Laverty W. Early onset Parkinson's disease and childhood environment. Adv Neurol. 1987;45:295–297. [PubMed]
  • Jiménez-Jiménez FJ, Mateo D, Giménez-Roldán S. Exposure to well water and pesticides in Parkinson's disease: a case-control study in the Madrid area. Mov Disord. 1992;7(2):149–152. [PubMed]
  • Rajput AH, Uitti RJ, Stern W, Laverty W. Early onset Parkinson's disease in Saskatchewan--environmental considerations for etiology. Can J Neurol Sci. 1986 Nov;13(4):312–316. [PubMed]
  • Golbe LI, Farrell TM, Davis PH. Case-control study of early life dietary factors in Parkinson's disease. Arch Neurol. 1988 Dec;45(12):1350–1353. [PubMed]
  • Jenner P, Schapira AH, Marsden CD. New insights into the cause of Parkinson's disease. Neurology. 1992 Dec;42(12):2241–2250. [PubMed]
  • Hammond EC, Horn D. Smoking and death rates: report on forty-four months of follow-up of 187,783 men. 2. Death rates by cause. J Am Med Assoc. 1958 Mar 15;166(11):1294–1308. [PubMed]
  • Doll R, Peto R. Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J. 1976 Dec 25;2(6051):1525–1536. [PMC free article] [PubMed]
  • Haack DG, Baumann RJ, McKean HE, Jameson HD, Turbek JA. Nicotine exposure and Parkinson disease. Am J Epidemiol. 1981 Aug;114(2):191–200. [PubMed]
  • Baron JA. Cigarette smoking and Parkinson's disease. Neurology. 1986 Nov;36(11):1490–1496. [PubMed]
  • Golbe LI, Cody RA, Duvoisin RC. Smoking and Parkinson's disease. Search for a dose-response relationship. Arch Neurol. 1986 Aug;43(8):774–778. [PubMed]
  • Yong VW, Perry TL. Monoamine oxidase B, smoking, and Parkinson's disease. J Neurol Sci. 1986 Feb;72(2-3):265–272. [PubMed]
  • Riggs JE. Smoking and Alzheimer's disease: protective effect or differential survival bias? Lancet. 1993 Sep 25;342(8874):793–794. [PubMed]
  • Ben-Shlomo Y. Smoking and neurogenerative diseases. Lancet. 1993 Nov 13;342(8881):1239–1239. [PubMed]
  • Bharucha NE, Stokes L, Schoenberg BS, Ward C, Ince S, Nutt JG, Eldridge R, Calne DB, Mantel N, Duvoisin R. A case-control study of twin pairs discordant for Parkinson's disease: a search for environmental risk factors. Neurology. 1986 Feb;36(2):284–288. [PubMed]
  • Forgays DG, Bonaiuto P, Wrzesniewski K, Forgays DK. Personality and cigarette smoking in Italy, Poland, and the United States. Int J Addict. 1993 Apr;28(5):399–413. [PubMed]
  • Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. [PubMed]
  • Forno LS, Alvord EC., Jr The pathology of Parkinsonism. Part I. Some new observations and correlations. Contemp Neurol Ser. 1971;8:119–130. [PubMed]
  • Mindham RH. Psychiatric symptoms in Parkinsonism. J Neurol Neurosurg Psychiatry. 1970 Apr;33(2):188–191. [PMC free article] [PubMed]
  • Robins AH. Depression in patients with Parkinsonism. Br J Psychiatry. 1976 Feb;128:141–145. [PubMed]
  • Santamaría J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology. 1986 Aug;36(8):1130–1133. [PubMed]
  • Koller WC. Sensory symptoms in Parkinson's disease. Neurology. 1984 Jul;34(7):957–959. [PubMed]
  • Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol. 1988;76(3):217–221. [PubMed]
  • Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988 Aug;38(8):1237–1244. [PubMed]
  • Lees AJ. When did Ray Kennedy's Parkinson's disease begin? Mov Disord. 1992;7(2):110–116. [PubMed]
  • Brooks DJ. Detection of preclinical Parkinson's disease with PET. Neurology. 1991 May;41(5 Suppl 2):24–28. [PubMed]
  • Wenning GK, Ben Shlomo Y, Magalhães M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994 Aug;117(Pt 4):835–845. [PubMed]
  • Brown RG, Marsden CD. How common is dementia in Parkinson's disease? Lancet. 1984 Dec 1;2(8414):1262–1265. [PubMed]
  • Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, Stern Y. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol. 1992 May;49(5):492–497. [PubMed]
  • Gibb WR, Luthert PJ, Janota I, Lantos PL. Cortical Lewy body dementia: clinical features and classification. J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):185–192. [PMC free article] [PubMed]
  • Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. [PMC free article] [PubMed]
  • Koller WC. Diagnosis and treatment of tremors. Neurol Clin. 1984 Aug;2(3):499–514. [PubMed]
  • Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992 Jun;42(6):1142–1146. [PubMed]
  • Marttila RJ, Rinne UK. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand. 1976 Feb;53(2):81–102. [PubMed]
  • Harada H, Nishikawa S, Takahashi K. Epidemiology of Parkinson's disease in a Japanese city. Arch Neurol. 1983 Mar;40(3):151–154. [PubMed]
  • Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology. 1991 May;41(5):622–629. [PubMed]
  • Lees AJ. The on-off phenomenon. J Neurol Neurosurg Psychiatry. 1989 Jun;Suppl:29–37. [PMC free article] [PubMed]
  • Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology. 1984 Sep;34(9):1131–1136. [PubMed]
  • Olanow CW, Nakano K, Nausieda P, Tetrud JA, Manyam B, Last B, Block G, Liss C, Bush D. An open multicenter trial of Sinemet CR in levodopa-naive Parkinson's disease patients. Clin Neuropharmacol. 1991 Jun;14(3):235–240. [PubMed]
  • LeWitt PA, Gopinathan G, Ward CD, Sanes JN, Dambrosia JM, Durso R, Calne DB. Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study. Neurology. 1982 Jan;32(1):69–72. [PubMed]
  • LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster N, Dambrosia JM, Calne DB. Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology. 1983 Aug;33(8):1009–1014. [PubMed]
  • Laihinen A, Rinne UK, Suchy I. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease. Acta Neurol Scand. 1992 Dec;86(6):593–595. [PubMed]
  • Rinne UK. Strategies in the treatment of early Parkinson's disease. Acta Neurol Scand Suppl. 1993;146:50–53. [PubMed]
  • Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology. 1987 May;37(5):826–828. [PubMed]
  • Weiner WJ, Factor SA, Sanchez-Ramos JR, Singer C, Sheldon C, Cornelius L, Ingenito A. Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology. 1993 Jan;43(1):21–27. [PubMed]
  • Swanson PD. Drug treatment of Parkinson's disease: is "polypharmacy" best? J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):401–403. [PMC free article] [PubMed]
  • Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988 Feb 20;1(8582):403–406. [PubMed]
  • Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, Stern GM. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord. 1993 Apr;8(2):165–170. [PubMed]
  • Eisler T, Teräväinen H, Nelson R, Krebs H, Weise V, Lake CR, Ebert MH, Whetzel N, Murphy DL, Kopin IJ, et al. Deprenyl in Parkinson disease. Neurology. 1981 Jan;31(1):19–23. [PubMed]
  • Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease. Neurology. 1989 Aug;39(8):1109–1111. [PubMed]
  • Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989 Aug 4;245(4917):519–522. [PubMed]
  • Elizan TS, Yahr MD, Moros DA, Mendoza MR, Pang S, Bodian CA. Selegiline use to prevent progression of Parkinson's disease. Experience in 22 de novo patients. Arch Neurol. 1989 Dec;46(12):1275–1279. [PubMed]
  • Schulzer M, Mak E, Calne DB. The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol. 1992 Dec;32(6):795–798. [PubMed]
  • Calne DB. Treatment of Parkinson's disease. N Engl J Med. 1993 Sep 30;329(14):1021–1027. [PubMed]
  • Stoof JC, Booij J, Drukarch B, Wolters EC. The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol. 1992 Mar 31;213(3):439–443. [PubMed]
  • Caradoc-Davies TH, Weatherall M, Dixon GS. Medications and their monitoring in Parkinson's disease in Dunedin. N Z Med J. 1992 Jun 10;105(935):212–214. [PubMed]
  • Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord. 1993 Apr;8(2):129–133. [PubMed]
  • Perry TL, Yong VW, Ito M, Foulks JG, Wall RA, Godin DV, Clavier RM. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem. 1984 Oct;43(4):990–993. [PubMed]
  • Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord. 1986;1(1):65–68. [PubMed]
  • Calne DB. The free radical hypothesis in idiopathic parkinsonism: evidence against it. Ann Neurol. 1992 Dec;32(6):799–803. [PubMed]
  • Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol. 1987 Jul;22(1):8–12. [PubMed]
  • Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology. 1990 Feb;40(2):340–345. [PubMed]
  • Frankel JP, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96–101. [PMC free article] [PubMed]
  • Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg. 1992 Jan;76(1):53–61. [PubMed]
  • Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet. 1995 Jan 14;345(8942):91–95. [PubMed]
  • Goetz CG, Stebbins GT, 3rd, Klawans HL, Koller WC, Grossman RG, Bakay RA, Penn RD. United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants: presurgical, and 1- and 2-year follow-up. Neurology. 1991 Nov;41(11):1719–1722. [PubMed]
  • Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B, Frackowiak R, Leenders KL, Sawle G, Rothwell JC, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol. 1992 Feb;31(2):155–165. [PubMed]
  • Sawle GV, Bloomfield PM, Björklund A, Brooks DJ, Brundin P, Leenders KL, Lindvall O, Marsden CD, Rehncrona S, Widner H, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol. 1992 Feb;31(2):166–173. [PubMed]
  • Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B, Björklund A, Lindvall O, Langston JW. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) N Engl J Med. 1992 Nov 26;327(22):1556–1563. [PubMed]
  • Freed CR, Breeze RE, Rosenberg NL, Schneck SA, Kriek E, Qi JX, Lone T, Zhang YB, Snyder JA, Wells TH, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med. 1992 Nov 26;327(22):1549–1555. [PubMed]
  • Spencer DD, Robbins RJ, Naftolin F, Marek KL, Vollmer T, Leranth C, Roth RH, Price LH, Gjedde A, Bunney BS, et al. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med. 1992 Nov 26;327(22):1541–1548. [PubMed]
  • Formisano R, Pratesi L, Modarelli FT, Bonifati V, Meco G. Rehabilitation and Parkinson's disease. Scand J Rehabil Med. 1992 Sep;24(3):157–160. [PubMed]
  • Yekutiel MP. Patients' fall records as an aid in designing and assessing therapy in Parkinsonism. Disabil Rehabil. 1993 Oct-Dec;15(4):189–193. [PubMed]
  • Gibberd FB, Page NG, Spencer KM, Kinnear E, Hawksworth JB. Controlled trial of physiotherapy and occupational therapy for Parkinson's disease. Br Med J (Clin Res Ed) 1981 Apr 11;282(6271):1196–1196. [PMC free article] [PubMed]
  • Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey. Folia Phoniatr Logop. 1994;46(1):9–17. [PubMed]
  • Le Dorze G, Dionne L, Ryalls J, Julien M, Ouellet L. The effects of speech and language therapy for a case of dysarthria associated with Parkinson's disease. Eur J Disord Commun. 1992;27(4):313–324. [PubMed]
  • Scott S, Caird FI. Speech therapy for patients with Parkinson's disease. Br Med J (Clin Res Ed) 1981 Oct 24;283(6299):1088–1088. [PMC free article] [PubMed]

Articles from The British Journal of General Practice are provided here courtesy of Royal College of General Practitioners